Project 1: Base Repair: Molecular response to base-modifying chemotherapeutic agents
项目1:碱基修复:碱基修饰化疗药物的分子反应
基本信息
- 批准号:10492028
- 负责人:
- 金额:$ 23.98万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2001
- 资助国家:美国
- 起止时间:2001-09-27 至 2026-08-31
- 项目状态:未结题
- 来源:
- 关键词:Alkylating AgentsAlkylationApoptosisAreaBase Excision RepairsBiochemistryBiological AssayBiophysicsCancer BiologyCell LineCell SurvivalCellsCellular biologyCisplatinComplexCryoelectron MicroscopyCrystallographyDNADNA DamageDNA RepairDNA Repair PathwayDefectDiseaseDrug resistanceEndoribonucleasesExcisionExposure toImmuneIndividualInterferonsKnowledgeLesionMalignant NeoplasmsMeasuresMediatingMethodsMethylationModalityModificationMolecularNeoadjuvant TherapyNucleic AcidsNucleotidesPathway interactionsPatternPharmacotherapyPlatinum CompoundsPositioning AttributeRNARepair ComplexRoentgen RaysRoleSignal PathwaySignal TransductionStructureSystemTestingWorkadductbasebiophysical modelcancer therapychemotherapeutic agentchemotherapyclinically relevantclinically significantcrosslinkendonucleasegenotoxicityhelicaseinsightmolecular modelingmultidisciplinarymutantneoplastic cellnovelnucleaseprogramsrepairedresponsestructural biologytherapy resistanttumor
项目摘要
SUMMARY - PROJECT 1: Molecular response to base-modifying chemotherapeutic agents
Repair of base damage on DNA is critical because such damage is both genotoxic and mutagenic. Many
chemotherapeutic agents used for cancer therapy, such as cisplatin and alkylating agents, induce this type of
damage and are one of the most commonly used modalities for treatment, underscoring their clinical significance.
While much is known about how cells respond to DNA containing base damage, the importance of RNA damage
has become increasingly appreciated only recently. Indeed, alkylated RNA is estimated to comprise the vast
majority of the damaged nucleic acid in cells treated with such agents. It is not surprising then that cells have
evolved a number of mechanisms to cope with damaged RNA. We have discovered that the ALKBH3-ASCC
repair complex mediates the cellular response to DNA as well RNA base damage. This complex also interfaces
with the innate immune or DAMP (damage-associated molecular pattern) signaling through a novel RNA
endonuclease activity, which we have recently uncovered through the multidisciplinary efforts of this program
project. Our work implicates RNA damage recognition and signaling as a critical node in the cellular response to
base damage, an underexplored area, which we seek to understand in this renewal application. Specifically, we
will use a combination of structural methods and biochemistry to reveal the mechanistic basis of the enzymatic
activities within the ALKBH3-ASCC complex (Aim 1). We will also determine the importance of ASCC-mediated,
RNA-dependent DAMP signaling in the response to commonly used chemotherapeutic agents and its role in cell
fate decisions (Aim 2). Finally, we will determine how the ALKBH3-ASCC pathway integrates with established
base repair pathways, potentially identifying novel additive or synthetic lethal relationships between these
pathways (Aim 3). Together, the proposed work will reveal important insights into the contribution of RNA as well
as DNA base damage responses and its relevance to tumor cell eradication.
摘要 - 项目 1:对碱基修饰化疗药物的分子反应
DNA 碱基损伤的修复至关重要,因为这种损伤既具有遗传毒性又具有诱变性。许多
用于癌症治疗的化疗药物,例如顺铂和烷化剂,会诱导这种类型的
损伤,是最常用的治疗方式之一,强调了其临床意义。
虽然人们对细胞如何响应含有碱基损伤的 DNA 知之甚多,但 RNA 损伤的重要性
直到最近才变得越来越受重视。事实上,据估计,烷基化 RNA 包含大量
用此类试剂处理的细胞中的大部分核酸被破坏。那么细胞具有
进化出许多机制来应对受损的RNA。我们发现 ALKBH3-ASCC
修复复合物介导细胞对 DNA 和 RNA 碱基损伤的反应。这个综合体还接口
通过新型 RNA 进行先天免疫或 DAMP(损伤相关分子模式)信号传导
我们最近通过该计划的多学科努力发现了核酸内切酶活性
项目。我们的工作表明 RNA 损伤识别和信号传导是细胞响应的关键节点
基础损坏是一个尚未开发的领域,我们希望在此更新申请中了解这一点。具体来说,我们
将结合结构方法和生物化学来揭示酶促作用的机制基础
ALKBH3-ASCC 复合体内的活动(目标 1)。我们还将确定 ASCC 介导的重要性,
RNA依赖性DAMP信号传导对常用化疗药物的反应及其在细胞中的作用
命运决定(目标 2)。最后,我们将确定 ALKBH3-ASCC 通路如何与已建立的
碱基修复途径,有可能识别这些之间的新的加成或合成致死关系
途径(目标 3)。总之,拟议的工作也将揭示有关 RNA 贡献的重要见解
DNA 碱基损伤反应及其与肿瘤细胞根除的相关性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Susan Emiko Tsutakawa其他文献
Susan Emiko Tsutakawa的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Susan Emiko Tsutakawa', 18)}}的其他基金
Towards Accurate Protein Structure Predictions with SAXS Technology (TAPESTRY)
利用 SAXS 技术 (TAPESTRY) 实现准确的蛋白质结构预测
- 批准号:
10418659 - 财政年份:2020
- 资助金额:
$ 23.98万 - 项目类别:
Towards Accurate Protein Structure Predictions with SAXS Technology (TAPESTRY)
利用 SAXS 技术 (TAPESTRY) 实现准确的蛋白质结构预测
- 批准号:
10171872 - 财政年份:2020
- 资助金额:
$ 23.98万 - 项目类别:
Towards Accurate Protein Structure Predictions with SAXS Technology (TAPESTRY)
利用 SAXS 技术 (TAPESTRY) 实现准确的蛋白质结构预测
- 批准号:
10624898 - 财政年份:2020
- 资助金额:
$ 23.98万 - 项目类别:
Project 1: Base Repair: Molecular response to base-modifying chemotherapeutic agents
项目1:碱基修复:碱基修饰化疗药物的分子反应
- 批准号:
10271092 - 财政年份:2001
- 资助金额:
$ 23.98万 - 项目类别:
相似国自然基金
低价钴-氢催化烯烃/炔烃氢烷基化
- 批准号:22371273
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
镍催化非活化烯烃的多组分还原双烷基化反应
- 批准号:22301290
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
ZnCeZrOx@ZSM-5双功能催化剂的构建及催化二氧化碳加氢与苯烷基化性能研究
- 批准号:22309130
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
光电协同多组分氟烷基化/环化同步反应及应用研究
- 批准号:22378360
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
吡啶间位碳氢键的不对称烷基化反应研究
- 批准号:22371141
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
相似海外基金
Novel therapeutics for the targeted eradication of DDR-defective tumors
靶向根除 DDR 缺陷肿瘤的新疗法
- 批准号:
10734414 - 财政年份:2023
- 资助金额:
$ 23.98万 - 项目类别:
Modeling the Responsiveness of Sensitive Populations to Genotoxic Agents Using DNA Repair Inhibitors
使用 DNA 修复抑制剂模拟敏感人群对基因毒性药物的反应性
- 批准号:
10734425 - 财政年份:2023
- 资助金额:
$ 23.98万 - 项目类别:
Development of Targeted Damaging Agents for the Treatment of Drug-Resistant Gliomas
开发治疗耐药神经胶质瘤的靶向损伤剂
- 批准号:
10481979 - 财政年份:2022
- 资助金额:
$ 23.98万 - 项目类别:
Development of Targeted Damaging Agents for the Treatment of Drug-Resistant Gliomas
开发治疗耐药神经胶质瘤的靶向损伤剂
- 批准号:
10812561 - 财政年份:2022
- 资助金额:
$ 23.98万 - 项目类别:
Mechanisms and therapeutic implications of temozolomide resistance in glioblastoma
胶质母细胞瘤替莫唑胺耐药的机制和治疗意义
- 批准号:
10463343 - 财政年份:2022
- 资助金额:
$ 23.98万 - 项目类别: